BR112021013944A2 - - Google Patents

Info

Publication number
BR112021013944A2
BR112021013944A2 BR112021013944A BR112021013944A BR112021013944A2 BR 112021013944 A2 BR112021013944 A2 BR 112021013944A2 BR 112021013944 A BR112021013944 A BR 112021013944A BR 112021013944 A BR112021013944 A BR 112021013944A BR 112021013944 A2 BR112021013944 A2 BR 112021013944A2
Authority
BR
Brazil
Application number
BR112021013944A
Other versions
BR112021013944A8 (pt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BR112021013944A2 publication Critical patent/BR112021013944A2/pt
Publication of BR112021013944A8 publication Critical patent/BR112021013944A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2334—Interleukin-34 (IL-34)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
BR112021013944A 2019-01-15 2020-01-15 Polipeptídeos de interleucina-34 (il-34) mutada e usos dos mesmos em terapias BR112021013944A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19305046 2019-01-15
PCT/EP2020/050920 WO2020148338A1 (en) 2019-01-15 2020-01-15 Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy

Publications (2)

Publication Number Publication Date
BR112021013944A2 true BR112021013944A2 (pt) 2021-11-21
BR112021013944A8 BR112021013944A8 (pt) 2023-02-07

Family

ID=65228484

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021013944A BR112021013944A8 (pt) 2019-01-15 2020-01-15 Polipeptídeos de interleucina-34 (il-34) mutada e usos dos mesmos em terapias

Country Status (12)

Country Link
US (1) US20220098264A1 (pt)
EP (1) EP3911670A1 (pt)
JP (1) JP2022517029A (pt)
KR (1) KR20210121077A (pt)
CN (1) CN113508129A (pt)
AU (1) AU2020208909A1 (pt)
BR (1) BR112021013944A8 (pt)
CA (1) CA3126741A1 (pt)
IL (1) IL284868A (pt)
MX (1) MX2021008525A (pt)
SG (1) SG11202107606VA (pt)
WO (1) WO2020148338A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023246908A1 (zh) * 2022-06-21 2023-12-28 四川大学华西医院 靶向csf1r的嵌合抗原受体免疫细胞制备及其应用
CN115819614B (zh) * 2022-06-21 2024-02-23 四川大学华西医院 一种基于il34的嵌合抗原受体免疫细胞制备及其应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR520E (fr) 1901-11-13 1903-01-26 Bermont Victor Etienne Procédé industriel d'extraction directe du zinc contenu dans les minerais oxydés, et plus spécialement dans la smithsonite (znco3) et la calamine (h2zn2sio5)
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
DE69034078T2 (de) 1989-03-21 2004-04-01 Vical, Inc., San Diego Expression von exogenen Polynukleotidsequenzen in Wirbeltieren
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
WO1994004678A1 (en) 1992-08-21 1994-03-03 Casterman Cecile Immunoglobulins devoid of light chains
DE69434860T2 (de) 1993-02-22 2007-03-15 The Rockefeller University Herstellung von helfer-freien retroviren mit hohem titer mittels transienter transfektion
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
WO1995028494A1 (en) 1994-04-15 1995-10-26 Targeted Genetics Corporation Gene delivery fusion proteins
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
JP2001523958A (ja) 1997-03-21 2001-11-27 ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド 免疫療法のｃｔｌａ−４結合ペプチド
CZ303703B6 (cs) 1998-12-23 2013-03-20 Pfizer Inc. Monoklonální protilátka nebo její antigen-vázající fragment, farmaceutická kompozice obsahující tuto protilátku nebo fragment, bunecná linie produkující tuto protilátku nebo fragment, zpusob prípravy této protilátky, izolovaná nukleová kyselina kóduj
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
EP3214175A1 (en) 1999-08-24 2017-09-06 E. R. Squibb & Sons, L.L.C. Human ctla-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
JP2003520828A (ja) 2000-01-27 2003-07-08 ジェネティクス インスティテュート，エルエルシー Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
SI1935427T1 (en) 2000-07-03 2018-05-31 Bristol-Myers Squibb Company USE OF HEATED CTLA4 MUTANT MOLECULES
JP2005506990A (ja) 2001-10-19 2005-03-10 アイソテクニカ インコーポレーテッド 新規のシクロスポリン類似体のマイクロエマルションプレコンセントレート
MXPA05004022A (es) 2002-10-17 2005-10-05 Genmab As Anticuerpos monoclonales humanos contra cd20.
ATE514713T1 (de) 2002-12-23 2011-07-15 Wyeth Llc Antikörper gegen pd-1 und ihre verwendung
ATE540973T1 (de) * 2004-07-22 2012-01-15 Five Prime Therapeutics Inc Zusammensetzungen und verfahren zur verwendung von mgd-cdf zur krankheitsbehandlung
NZ563193A (en) 2005-05-09 2010-05-28 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
DK1907424T3 (en) 2005-07-01 2015-11-09 Squibb & Sons Llc HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED death ligand 1 (PD-L1)
WO2007076354A2 (en) 2005-12-20 2007-07-05 Bristol-Myers Squibb Company Stable protein formulations
CN101970499B (zh) 2008-02-11 2014-12-31 治疗科技公司 用于肿瘤治疗的单克隆抗体
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
SI2350129T1 (sl) 2008-08-25 2015-11-30 Amplimmune, Inc. Sestavki PD-1 antagonistov in postopek njihove uporabe
CN102203125A (zh) 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1拮抗剂及其使用方法
CN108997498A (zh) 2008-12-09 2018-12-14 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
JP5748653B2 (ja) 2009-04-10 2015-07-15 協和発酵キリン株式会社 抗ｔｉｍ−３抗体を用いた血液腫瘍治療法
US8345509B2 (en) 2009-04-16 2013-01-01 Chevron U.S.A., Inc. System and method to create three-dimensional images of non-linear acoustic properties in a region remote from a borehole
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
DK3279215T3 (da) 2009-11-24 2020-04-27 Medimmune Ltd Målrettede bindemidler mod b7-h1
ES2682078T3 (es) 2010-06-11 2018-09-18 Kyowa Hakko Kirin Co., Ltd. Anticuerpo anti-TIM-3
US8841418B2 (en) 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
SI2785375T1 (sl) 2011-11-28 2020-11-30 Merck Patent Gmbh Protitelesa proti PD-L1 in uporabe le-teh
AU2014235750B2 (en) 2013-03-15 2018-05-17 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase (IDO)
HUE038169T2 (hu) 2013-09-06 2018-09-28 Aurigene Discovery Tech Ltd 1,2,4-Oxadiazol származékok mint immunomodulátorok
KR20160081898A (ko) 2013-09-06 2016-07-08 오리진 디스커버리 테크놀로지스 리미티드 면역조절제로서 1,3,4-옥사디아졸 및 1,3,4-티아디아졸 유도체
JP6769948B2 (ja) * 2014-07-17 2020-10-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 移植拒絶の予防及び自己免疫疾患の治療に使用するための単離されたインターロイキン−３４ポリペプチド
CN106084030B (zh) * 2016-04-25 2019-11-08 北京大学 一种提高白细胞介素il-34热稳定性的方法

Also Published As

Publication number Publication date
IL284868A (en) 2021-08-31
WO2020148338A1 (en) 2020-07-23
AU2020208909A1 (en) 2021-07-29
SG11202107606VA (en) 2021-08-30
JP2022517029A (ja) 2022-03-03
EP3911670A1 (en) 2021-11-24
MX2021008525A (es) 2021-11-12
CA3126741A1 (en) 2020-07-23
CN113508129A (zh) 2021-10-15
US20220098264A1 (en) 2022-03-31
KR20210121077A (ko) 2021-10-07
BR112021013944A8 (pt) 2023-02-07

Similar Documents

Publication Publication Date Title
BR112019017762A2 (pt)
BR112021017339A2 (pt)
BR112021018450A2 (pt)
BR112019016141A2 (pt)
BR112021017939A2 (pt)
BR112021017738A2 (pt)
BR112021017892A2 (pt)
BR112021017782A2 (pt)
AU2020104490A5 (pt)
BR112021017637A2 (pt)
BR112021008711A2 (pt)
BR112019016142A2 (pt)
BR112019016138A2 (pt)
BR112021018168A2 (pt)
BR112021017728A2 (pt)
BR112021018452A2 (pt)
BR112021017234A2 (pt)
BR112021017355A2 (pt)
BR112021017703A2 (pt)
BR112021018102A2 (pt)
BR112021017173A2 (pt)
BR112021018584A2 (pt)
BR112021017083A2 (pt)
BR112021015080A2 (pt)
BR112021012348A2 (pt)

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) ; NANTES UNIVERSITE (FR)